Literature DB >> 2386737

Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.

S P Langdon1, M M Hawkes, S S Lawrie, R A Hawkins, A L Tesdale, A J Crew, W R Miller, J F Smyth.   

Abstract

To assess the role of oestrogen regulation in the growth of ovarian cancer, we examined the effects of an oestrogen, 17 beta-oestradiol, and an anti-oestrogen, tamoxifen, on oestrogen receptor (ER) -positive and -negative human ovarian carcinoma cell lines. As measured by a dextran-coated charcoal adsorption assay, cell lines PEO1, PEO4 and PEO6 possessed moderate concentrations of ER (96-132 fmol mg-1 protein), PEA1 and PEA2 had low values (12-23 fmol mg-1 protein) and PEO14, TO14, PEO23 and PEO16 were ER-negative. Addition of 17 beta-oestradiol (10 nM or 0.1 nM) to the ER +ve cell line, PEO4, increased the growth rate. This oestrogen stimulation could be blocked by 1 microM tamoxifen. In contrast, the growth rate of the ER -ve cell line PEO14 was unaffected by the addition of 17 beta-oestradiol or tamoxifen. Concentrations of tamoxifen in excess of 8 microM were required to produce complete cytostasis in all lines. This concentration of tamoxifen over 72 hours also inhibited 50% colony formation when cells were plated on plastic. These data indicate that some ovarian carcinoma cell lines contain ER and their growth can be sensitive to oestrogen and anti-oestrogen modulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386737      PMCID: PMC1971801          DOI: 10.1038/bjc.1990.263

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues.

Authors:  R A Hawkins; A Hill; B Freedman
Journal:  Clin Chim Acta       Date:  1975-10-15       Impact factor: 3.786

2.  Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells.

Authors:  R L Sutherland; R E Hall; I W Taylor
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

3.  Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data.

Authors:  C Fabian; L Sternson; M El-Serafi; L Cain; E Hearne
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

4.  Characterization and properties of nine human ovarian adenocarcinoma cell lines.

Authors:  S P Langdon; S S Lawrie; F G Hay; M M Hawkes; A McDonald; I P Hayward; D J Schol; J Hilgers; R C Leonard; J F Smyth
Journal:  Cancer Res       Date:  1988-11-01       Impact factor: 12.701

5.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.

Authors:  T C Hamilton; R C Young; W M McKoy; K R Grotzinger; J A Green; E W Chu; J Whang-Peng; A M Rogan; W R Green; R F Ozols
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

6.  3H-estradiol and 3H-R5020 binding in cytosols of normal and neoplastic human ovarian tissue.

Authors:  K Pollow; A Schmidt-Matthiesen; G Hoffmann; G Schweikhart; R Kreienberg; B Manz; H J Grill
Journal:  Int J Cancer       Date:  1983-05-15       Impact factor: 7.396

7.  Estrogen and progesterone receptors in ovarian neoplasms.

Authors:  L C Ford; J S Berek; L D Lagasse; N F Hacker; Y Heins; F Esmailian; R S Leuchter; R J DeLange
Journal:  Gynecol Oncol       Date:  1983-06       Impact factor: 5.482

8.  Tamoxifen therapy for advanced ovarian cancer.

Authors:  P E Schwartz; G Keating; N MacLusky; F Naftolin; A Eisenfeld
Journal:  Obstet Gynecol       Date:  1982-05       Impact factor: 7.661

9.  Oestrogen receptor concentration in primary breast cancer and axillary node metastases.

Authors:  R A Hawkins; R Black; R J Steele; J M Dixon; A P Forrest
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

10.  Estrogen and progesterone receptor titers in primary epithelial ovarian carcinomas.

Authors:  L A Jones; C L Edwards; R S Freedman; M T Tan; H S Gallager
Journal:  Int J Cancer       Date:  1983-11-15       Impact factor: 7.396

View more
  15 in total

1.  p66Shc longevity protein regulates the proliferation of human ovarian cancer cells.

Authors:  Sakthivel Muniyan; Yu-Wei Chou; Te-Jung Tsai; Paul Thomes; Suresh Veeramani; Benedict B Benigno; L DeEtte Walker; John F McDonald; Shafiq A Khan; Fen-Fen Lin; Subodh M Lele; Ming-Fong Lin
Journal:  Mol Carcinog       Date:  2014-01-07       Impact factor: 4.784

2.  Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.

Authors:  Courtney L Andersen; Matthew J Sikora; Michelle M Boisen; Tianzhou Ma; Alec Christie; George Tseng; Yongseok Park; Soumya Luthra; Uma Chandran; Paul Haluska; Gina M Mantia-Smaldone; Kunle Odunsi; Karen McLean; Adrian V Lee; Esther Elishaev; Robert P Edwards; Steffi Oesterreich
Journal:  Clin Cancer Res       Date:  2017-01-10       Impact factor: 12.531

3.  Estrogen stimulation of ovarian surface epithelial cell proliferation.

Authors:  W Bai; B Oliveros-Saunders; Q Wang; M E Acevedo-Duncan; S V Nicosia
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Nov-Dec       Impact factor: 2.416

4.  Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.

Authors:  David M Gershenson; Diane C Bodurka; Robert L Coleman; Karen H Lu; Anais Malpica; Charlotte C Sun
Journal:  J Clin Oncol       Date:  2017-02-21       Impact factor: 44.544

5.  Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States).

Authors:  A I Adler; N S Weiss; M L Kamb; J L Lyon
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

6.  Aromatase excess in cancers of breast, endometrium and ovary.

Authors:  Serdar E Bulun; Dong Chen; Meiling Lu; Hong Zhao; Youhong Cheng; Masashi Demura; Bertan Yilmaz; Regina Martin; Hiroki Utsunomiya; Steven Thung; Emily Su; Erica Marsh; Amy Hakim; Ping Yin; Hiroshi Ishikawa; Sanober Amin; Gonca Imir; Bilgin Gurates; Erkut Attar; Scott Reierstad; Joy Innes; Zhihong Lin
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

7.  GPR30 predicts poor survival for ovarian cancer.

Authors:  Harriet O Smith; Hugo Arias-Pulido; Dennis Y Kuo; Tamara Howard; Clifford R Qualls; Sang-Joon Lee; Claire F Verschraegen; Helen J Hathaway; Nancy E Joste; Eric R Prossnitz
Journal:  Gynecol Oncol       Date:  2009-06-06       Impact factor: 5.482

8.  Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance.

Authors:  C Palmieri; O Gojis; B Rudraraju; C Stamp-Vincent; D Wilson; S Langdon; C Gourley; D Faratian
Journal:  Br J Cancer       Date:  2013-05-07       Impact factor: 7.640

9.  Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects.

Authors:  S J C Shan; A Scorilas; D Katsaros; E P Diamandis
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

10.  A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.

Authors:  M J Lind; B M Cantwell; M J Millward; A Robinson; M Proctor; D Simmons; J Carmichael; A L Harris
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.